藥品參考
Serplulimab
Serplulimab is a medicine in the class oncology. It is used for lung cancer.
- 藥物類別: Oncology
- 用途: lung cancer
最後更新 來源: EMA SmPC
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01FF12
- 常見劑型
- 溶液
- 常見規格
- 10 mg/ml
- 商品名
- 1
- 國家與市場
- 1
用途
作用方式
Humanised IgG4 monoclonal antibody that binds the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, potentiating T-cell responses including anti-tumour responses.
成人常用劑量（仿單摘要）
Extensive-stage SCLC (with carboplatin and etoposide): 4.5 mg/kg bodyweight, IV, every 3 weeks in induction (4 cycles) and maintenance, until disease progression or unacceptable toxicity
懷孕與哺乳
- 懷孕
- Unsafe No human data. PD-1 blockade causes embryo-fetal toxicity in animals, and IgG4 crosses the placenta. EU label: not recommended in pregnancy or without contraception; use effective contraception during treatment and for at least 6 months after the last dose.
- 哺乳
- Unsafe Not known if it passes into milk. EU label: risk to the infant cannot be excluded in the first days after birth; afterwards it could be used if needed. Other PD-1 antibody labels: avoid for 4 to 5 months after the last dose; nivolumab accumulated in one mother's milk. Avoid during treatment.
已通報的副作用
- Anaemia
- Neutropenia
- Leukopenia
- Thrombocytopenia
- Nausea
- Decreased appetite
禁忌症
- Hypersensitivity to the active substance or to any excipient.
哪些人需要特別留意
- Immune-mediated adverse reactions, including severe and fatal cases, can occur, up to 3.6 months after the last dose; withhold and give corticosteroids (1-2 mg/kg/day prednisone or equivalent) according to severity.
- Monitor for immune-mediated pneumonitis, colitis, hepatitis (monthly liver tests), nephritis (monthly renal function), endocrinopathies, skin reactions, pancreatitis and myocarditis.
- Infusion-related reactions can occur; monitor patients, reduce rate or interrupt for Grade 2, stop permanently for Grade ≥ 3.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
同類別的其他藥品
常見問題
What is Serplulimab used for?
Serplulimab is a medicine in the class oncology. It is used for Lung cancer, Non-small cell lung cancer.
What side effects have been reported with Serplulimab?
Anaemia, Neutropenia, Leukopenia, Thrombocytopenia, Nausea, Decreased appetite.
Can Serplulimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No human data. PD-1 blockade causes embryo-fetal toxicity in animals, and IgG4 crosses the placenta. EU label: not recommended in pregnancy or without contraception; use effective contraception during treatment and for at least 6 months after the last dose. Breastfeeding: Unsafe. Not known if it passes into milk. EU label: risk to the infant cannot be excluded in the first days after birth; afterwards it could be used if needed. Other PD-1 antibody labels: avoid for 4 to 5 months after the last dose; nivolumab accumulated in one mother's milk. Avoid during treatment.
What does Serplulimab interact with?
MediHelp does not list a checked interaction for Serplulimab yet. Always tell your pharmacist about every medicine you take.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
